When was Raphas founded?

Raphas was founded in 2006 and raised its 1st funding round 10 years after it was founded.

Where is Raphas located?

Raphas is headquartered in Seoul, South Korea.

How many employees does Raphas have?

As of Aug 31, 2026, the latest employee count at Raphas is 14.

Is Raphas a funded company?

Raphas is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Mar 17, 2016.

When was the latest funding round of Raphas?

Raphas' latest funding was a $***** Seed round on Mar 17, 2016, with participation from 1 investor. Its primary sector is Drug Delivery. In South Korea, the Drug Delivery sector has seen $27M in funding in 2026 to date.

Where does Raphas rank among its competitors?

Raphas ranks 6th amongst 26 active competitors, of which 9 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Terrestrial, which secured $57.3M in Mar, 2026.

Who are the top competitors of Raphas?

Raphas' top competitors include Insulet, Micron Biomedical and Enable Injections. Among them, Terrestrial secured the most recent funding round in March, 2026.

Raphas - 2026 Company Profile, Team, Funding & Competitors

Raphas is a public company based in Seoul (South Korea), founded in 2006. It operates as a Developer of microneedle technology for cosmetics and medical applications. Raphas has raised an undisclosed amount in funding. The company has 26 active competitors, including 9 funded and 3 that have exited. Its top competitors include companies like Insulet, Micron Biomedical and Enable Injections.

Company Details

Developer of microneedle technology for cosmetics and medical applications. This company manufactures microneedles for transdermal drug delivery and produces cosmetic and food products utilizing this technology. The company holds various certifications and approvals for its products in multiple regions. Its offerings include a cosmetic brand featuring microneedle technologies and a brand of health-focused food products.

Key Metrics

Founded Year

2006

Location

Seoul, South Korea

Stage

Public

Latest Funding Round

Seed, Mar 17, 2016, $*****

Investors

L&S Venture Capital & 6 more

Ranked

6^th among 26 active competitors

Employee Count

14 as on Aug 31, 2026

Similar Companies

Insulet & 25 more

Exit Details

Public

View Raphas' full profile

Raphas got listed on Nov 11, 2019.

Click here to take a look at Raphas's IPO in detail

Raphas has raised funding over 1 round. Its latest funding round was a Seed round on Mar 17, 2016 for $*****. 1 investor participated in its latest round. Raphas has 7 institutional investors.

Here is the list of recent funding rounds of Raphas:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 17, 2016	7001639	Seed	9614049	9351631	4373295	2288884

Access funding benchmarks and valuations. Sign up today!

View details of Raphas's funding rounds and investors

Raphas' employee count trend

Raphas has 14 employees as of Aug 26. Here is Raphas's employee count trend over the years:

Uncover Raphas' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Raphas include Insulet, Micron Biomedical and Enable Injections. Here is the list of Top 10 competitors of Raphas, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Insulet 2000, Boston (United States), Public	Manufacturer of wearable, tubeless insulin delivery systems for diabetes management	$120M	Federated Hermes, Piper Jaffray & 13 others	74/100
2nd	Micron Biomedical 2014, Atlanta (United States), Series A	Developer of microneedle patch technology for vaccines and drugs delivery	$33M	Global Health Investment, J2 Ventures & 10 others	60/100
3rd	Enable Injections 2010, Cincinnati (United States), Series C	Provider of a wearable drug delivery solution	$334M	Sanofi, Magnetar & 13 others	59/100
4th	Terrestrial 2011, Woburn (United States), Series C	Developer of a microarray patch platform for therapeutic delivery	$57.3M	RA Capital Management, Engine Ventures & 2 others	39/100
5th	Zosano Pharma 2006, Fremont (United States), Deadpooled	Developer of transdermal drug delivery systems for a broad range of therapeutic indications	$147M	Nomura, ProQuest Investments & 9 others	36/100
6th	Raphas 2006, Seoul (South Korea), Public	Developer of microneedle technology for cosmetics and medical applications	-	L&S Venture Capital, NHN Investment & 5 others	35/100
7th	SkinJect 2015, Pittsburgh (United States), Series A	Developer of microneedle patch to treat skin cancer	$2.5M	Topanga Partners, Velocity Fund Partners	34/100
8th	Array Patch 2019, Dublin (Ireland), Seed	Developer of microneedle patch technology for targeted drug delivery applications	$1.9M	Lakesidecapital, Boole Angel Investment Syndicate ... & 1 others	33/100
9th	Innovodigm 2018, Kolkata (India), Seed	Developer of vaccine delivery devices	$635K	Indian Angel Network, BIRAC & 1 others	32/100
10th	OBaris 2024, Schlieren (Switzerland), Acquired	Developer of a needle-free, self-applicable transdermal patch for injectables	-	-	31/100